- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2017-4-14 12:01 编辑
A Potent HBsAg Response in Subjects with Inactive HBsAg Carrier Treated with Pegylated-interferon Alpha
Authors
Zhenhuan Cao1†, MD, Yali Liu1†, MD, Lina Ma1, BS, Junfeng Lu1, MD, Yi Jin1, MS, Shan Ren1,MD, Zhimin He1, BS, Chengli Shen2*, MD Ph.D., Xinyue Chen1*, MS
†Those authors contributed equally to this work
1International Medical Department, Beijing Youan Hospital, Capital Medical University, Beijing,
100069 China
2Section on Biomarkers and Prediction Modeling, Department of Medicine, University of
Pittsburgh, Pittsburgh, PA, 15261 USA
Accepted manuscript online: 13 April 2017Full publication history
DOI: 10.1002/hep.29213 View/save citation
Cited by (CrossRef): 0 articles Check for updates
Abstract
Background: HBsAg clearance represents a clinical cure although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated-interferon α-2a (PEG-IFNα-2a) as a therapeutic option for inactive HBsAg carriers (IHCs). Methods: 144 IHCs were enrolled and divided into a therapeutic group (102 subjects) and control group (42 subjects). PEG-IFNα-2a and PEG-IFNα-2a combined with Adefovir Dipivoxil (ADV) were used for treatment group subjects with hepatitis B virus (HBV) DNA <20 IU/mL and 20 IU/mL≤HBV DNA<2000 IU/mL, respectively. Total therapy duration was no more than 96 weeks. HBsAg clearance and seroconversion rates at the therapeutic week 48 and 96 were used to evaluate the therapeutic efficacy. Results: Per-protocol (PP) analysis showed that HBsAg clearance rate and seroconversion rate in the treatment group were 29.8% and 20.2% at week 48, increased to 44.7% and 38.3% at week 96. However, the HBsAg clearance rate in control group was 2.4% at weeks 48 and 96, and no subject achieved seroconversion. The quantitative HBsAg levels and the changes during the early period of treatment (at week 12 and week 24), alanine transaminase (ALT) elevation at week 12 were strong predictors of HBsAg clearance. The adverse events were similar to the treatment for chronic hepatitis B patients.
Conclusion: High rates of HBsAg clearance and seroconversion could achieve by PEG-IFN α-2a based treatments and the treatments were relatively safe for IHCs. This article is protected by copyright. All rights reserved.
|
|